ArticleARYA atherosclerosis2015
Applying the Framingham risk score for prediction of metabolic syndrome: The Kerman Coronary Artery Disease Risk Study, Iran.
Article in ARYA atherosclerosis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The impacts of Crocin on serum cytokines concentrations in participants with metabolic syndrome: a double-blind randomized clinical trial study.Scientific reports · 2025Trial
- Framingham risk scores for determination the 10-year risk of cardiovascular disease in participants with and without the metabolic syndrome: results of the Fasa Persian cohort study.BMC endocrine disorders · 2024Article
- Risk estimation of cardiovascular diseases using the World Health Organization/International Society of Hypertension risk prediction charts in the Azar cohort population: Cross-sectional study.Journal of cardiovascular and thoracic research · 2024Article
- Impact of modifiable risk factors on prediction of 10-year cardiovascular disease utilizing framingham risk score in Southwest Iran.BMC cardiovascular disorders · 2023Article
- Inflammatory Cytokines, Redox Status, and Cardiovascular Diseases Risk after Weight Loss via Bariatric Surgery and Lifestyle Intervention.Medicina (Kaunas, Lithuania) · 2023Article
- Association between 24-h movement guidelines and cardiometabolic health in Chilean adults.Scientific reports · 2022Article
- Predicting the natural history of metabolic syndrome with a Markov-system dynamic model: a novel approach.BMC medical research methodology · 2021Article
- Article
- Estimation of the 10-Year Risk of Cardiovascular Diseases: Using the SCORE, WHO/ISH, and Framingham Models in the Shahrekord Cohort Study in Southwestern Iran.The journal of Tehran Heart Center · 2020Article
- Comparison Between Metabolic Syndrome and the Framingham Risk Score as Predictors of Cardiovascular Diseases Among Kazakhs in Xinjiang.Scientific reports · 2018Article
- Self-reported hypertension in Northern China: a cross-sectional study of a risk prediction model and age trends.BMC health services research · 2018Article
- Framingham risk score for estimation of 10-years of cardiovascular diseases risk in patients with metabolic syndrome.Journal of health, population, and nutrition · 2017Article
- Prevalence of metabolic syndrome in Iran: A meta-analysis.Electronic physician · 2017Article
- Cardiovascular Risk Stratification in Patients with Metabolic Syndrome Without Diabetes or Cardiovascular Disease: Usefulness of Metabolic Syndrome Severity Score.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017Article
- Effect of crocin, a carotenoid from saffron, on plasma cholesteryl ester transfer protein and lipid profile in subjects with metabolic syndrome: A double blind randomized clinical trial.ARYA atherosclerosis · 2017Article
- Risk factors for the treatment outcome of retreated pulmonary tuberculosis patients in China: an optimized prediction model.Epidemiology and infection · 2017Article
- Metabolic Syndrome and Framingham Risk Score: Observation from Screening of Low-Income Semi-Urban African Women.Medicines (Basel, Switzerland) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere has been a few studies about the predictability of metabolic syndrome (MetS) based on the Framingham risk score (FRS) as a tool for predicting the risk of 10-years cardiovascular diseases (CVD) in Iranian population. The aim of this study was to compare the risk stratification obtained with the FRS and MetS in a cohort of the Iranian population.
methodsIn this population-based study Kerman Coronary Artery Disease Risk study, Iran, MetS was diagnosed as defined by the revised National Cholesterol Education Program definition criteria (ATPIII) and the FRS was calculated using a computer program, previously reported algorithm.
resultsOverall, the prevalence 10-years risk of CVD for patients with MetS was significantly different with those without MetS (74.3 vs. 86.4% for low-risk patients, 18.1 vs. 12.3% for intermediate-risk people, and 7.6 vs. 1.3% for high-risk individuals) (P < 0.001). The frequency of intermediate-risk and high-risk for 10-year CVD in men with MetS (39.5 and 18.3%, respectively) was considerably higher than women with MetS (3.2 and 0.1%, respectively). Using multiple logistic regression, the odds ratio of MetS in intermediate-risk and high-risk FRS group was 1.7 and 6.7, respectively (P < 0.001).
conclusionSignificant association between the presence of MetS and high risk for CVD based on FRS was revealed in both men and women indicating a good concordance between MetS and FRS in predicting the risk of CVDs. However, the odds ratio of the development of risk of cardiovascular events among women was higher than men with MetS.
Indexed as
Identifiers
26405450PMC4568190What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.